ESMO 2026 - Breast Cancer: ADCs & Biomarkers with Dr. Paolo Tarantino

Dr. Paolo Tarantino shares his ESMO highlights on selective CDK4 inhibitors, immunotherapy and emerging ADCs, alongside CHARISMA and the search for biomarkers to guide treatment selection and understand resistance.